Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Marker Therapeutics, Inc. (MRKR)
Last marker therapeutics, inc. earnings: 11/12 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durable objective responses after MT-601 treatment Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic
Show less
Read more
Impact Snapshot
Event Time:
MRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRKR alerts
High impacting Marker Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRKR
News
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results [Yahoo! Finance]Yahoo! Finance
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsGlobeNewswire
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceGlobeNewswire
- Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of DirectorsBusiness Wire
MRKR
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/8/24 - Form 8-K
- MRKR's page on the SEC website